ArticleBMC cancer2013
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.Translational andrology and urology · 2021Article
- Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors.BMC cancer · 2021Article
- Characterization ofCell cycle (Georgetown, Tex.) · 2020Article
- Frequent copy number gains of SLC2A3 and ETV1 in testicular embryonal carcinomas.Endocrine-related cancer · 2020Article
- HMGA1-Regulating microRNAs Let-7a and miR-26a are Downregulated in Human Seminomas.International journal of molecular sciences · 2020Article
- New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
- CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.Cancer biomarkers : section A of Disease markers · 2019Review
- The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Molecular cancer · 2018Review
- The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.Oncotarget · 2017Article
- MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors.Oncotarget · 2016Article
- Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.Oncotarget · 2015Article
- FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.Oncotarget · 2015Article
- The Warburg effect revisited--lesson from the Sertoli cell.Medicinal research reviews · 2015Review
Corrections and comments
- Retraction · 2021-01-27Duplication of/in Image · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDNA damage response has been clearly described as an anti-cancer barrier in early human tumorigenesis. Moreover, interestingly, testicular germ cell tumors (TGCTs) have been reported to lack the DNA Damage Response (DDR) pathway activation. CCDC6 is a pro-apoptotic phosphoprotein substrate of the kinase ataxia telangectasia mutated (ATM) able to sustain DNA damage checkpoint in response to genotoxic stress and is commonly rearranged in malignancies upon fusion with different partners. In our study we sought to determine whether CCDC6 could have a role in the patho-genesis of testicular germ cell tumors.
methodsTo achieve this aim, analysis for CCDC6 expression has been evaluated on serial sections of the mouse testis by immunohistochemistry and on separate populations of murine testicular cells by western blot. Next, the resistance to DNA damage-induced apoptosis and the production of reactive oxygen species has been investigated in GC1 cells, derived from immortalized type B murine germ cells, following CCDC6 silencing. Finally, the CCDC6 expression in normal human testicular cells, in Intratubular Germ Cell Neoplasia Unclassified (IGCNU), in a large series of male germ cell tumours and in the unique human seminoma TCam2 cell line has been evaluated by immunohistochemistry and by Western Blot analyses.
resultsThe analysis of the CCDC6 expression revealed its presence in Sertoli cells and in spermatogonial cells. CCDC6 loss was the most consistent feature among the primary tumours and TCam2 cells. Interestingly, following treatment with low doses of H₂O₂, the silencing of CCDC6 in GC1 cells caused a decrease in the oxidized form of cytochrome c and low detection of Bad, PARP-1 and Caspase 3 proteins. Moreover, in the silenced cells, upon oxidative damage, the cell viability was protected, the γH2AX activation was impaired and the Reactive Oxygen Species (ROS) release was decreased.
conclusionsTherefore, our results suggest that the loss of CCDC6 could aid the spermatogonial cells to be part of a pro-survival pathway that helps to evade the toxic effects of endogenous oxidants and contributes to testicular neoplastic growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.